论文部分内容阅读
过去的5～7年中人们把更多的注意力集中于新的4-喹诺酮药物的合成及评价上,因而发现了许多6-氟7-哌嗪-4-喹酮(6-fluoro-7-piperazino-4-quinolones)类药物。这些药物对革蓝氏阴性杆菌和球菌的体外抗菌活性的广度和强度以及口服能耐受剂量即可控制由实验性细菌引起的全身性感染的能力皆值得注意。其中活性最强的代表药物是氟哌酸(norfloxacin Bay 09867)、氨氟哌酸(amifloxacin,Win 49375)、氟啶酸(enoxacin,AT-2266,CI-919)以及甲氟哌酸(pefloxacin,1589-RB)等氟喹酮类药物。
In the past 5-7 years, more attention has been focused on the synthesis and evaluation of new 4-quinolone drugs, and many 6-fluoro-7-quinolones (6-fluoro-7 -piperazino-4-quinolones. The breadth and intensity of the in vitro antibacterial activity of these drugs against gram-negative bacilli and cocci, as well as their ability to orally tolerate doses to control systemic infections caused by experimental bacteria, are all noteworthy. The most active agents among them were norfloxacin Bay 09867, amifloxacin (Win 49375), enoxacin (AT-2266, CI-919) and pefloxacin 1589-RB) and other fluoroquinolones.